Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs).

作者: Victoria E. Price , Maria Zielenska , Susan Chilton-MacNeill , Charles. R. Smith , Alberto S. Pappo

DOI: 10.1002/PBC.20377

关键词:

摘要: Background To describe the clinical characteristics, molecular features, treatment, and outcome of six pediatric patients with gastrointestinal stromal tumors (GISTs). Patients Methods Retrospective review GISTs, seen at The Hospital for Sick Children (HSC) Toronto, over an 11-year period. All specimens were stained CD 117 34 antigens. Three sequenced mutations in exons 9, 11, 13 c-kit gene. Results Five evaluated treated HSC one was referred histopathological consultation only. median patient age diagnosis 13.6 years, (6.9–14.8 years); four female. presented anemia secondary to (GI) bleeding. disease localized five two had other malignancies consistent diagnoses Carney's triad. Immunohistochemical staining showed heavy cytoplasmic localization all tumor cells. A novel point mutation KIT codon 456 exon 9 found case. Complete surgical resection achieved managed our center none received adjuvant therapies. Disease recurred locally patient. Four are alive is lost follow-up. Conclusions In children adolescents, GISTs should be considered differential GI hemorrhage. absence 11 identification a suggest that may respond differently currently available targeted therapies therefore studied within context collaborative group trials. Pediatr Blood Cancer 2005; 45:20–24. © 2005 Wiley-Liss, Inc.

参考文章(23)
Monica S. Cypriano, Jesse J. Jenkins, Alberto S. Pappo, Bhaskar N. Rao, Najat C. Daw, Pediatric Gastrointestinal Stromal Tumors and Leiomyosarcoma The St. Jude Children's Research Hospital Experience and a Review of the Literature Cancer. ,vol. 101, pp. 39- 50 ,(2004) , 10.1002/CNCR.20352
Lisa Sarran, Peter Besmer, Ronald P DeMatteo, Sylvia J Tschernyavsky, Marc Ladanyi, Robert Maki, Mark Robson, Elyn Riedel, James M Woodruff, Murray F Brennan, Cristina R Antonescu, Gunhild Sommer, Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clinical Cancer Research. ,vol. 9, pp. 3329- 3337 ,(2003)
H Kitayama, Y Kanakura, T Furitsu, T Tsujimura, K Oritani, H Ikeda, H Sugahara, H Mitsui, Y Kanayama, Y Kitamura, Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood. ,vol. 85, pp. 790- 798 ,(1995) , 10.1182/BLOOD.V85.3.790.BLOODJOURNAL853790
Jerzy Lasota, Agnieszka Wozniak, Maarit Sarlomo-Rikala, Janusz Rys, Radzislaw Kordek, Aziza Nassar, Leslie H. Sobin, Markku Miettinen, Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. American Journal of Pathology. ,vol. 157, pp. 1091- 1095 ,(2000) , 10.1016/S0002-9440(10)64623-8
S Majumder, K Brown, F H Qiu, P Besmer, c-kit protein, a transmembrane kinase: identification in tissues and characterization. Molecular and Cellular Biology. ,vol. 8, pp. 4896- 4903 ,(1988) , 10.1128/MCB.8.11.4896
Allan T van Oosterom, Ian Judson, Jaap Verweij, Sigrid Stroobants, Eugenio Donato di Paola, Sasa Dimitrijevic, Marc Martens, Andrew Webb, Raf Sciot, Martine Van Glabbeke, Sandra Silberman, Ole S Nielsen, Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. The Lancet. ,vol. 358, pp. 1421- 1423 ,(2001) , 10.1016/S0140-6736(01)06535-7
Marcia L. Lux, Brian P. Rubin, Tara L. Biase, Chang-Jie Chen, Timothy Maclure, George Demetri, Sheng Xiao, Samuel Singer, Christopher D.M. Fletcher, Jonathan A. Fletcher, KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. American Journal of Pathology. ,vol. 156, pp. 791- 795 ,(2000) , 10.1016/S0002-9440(10)64946-2
Michael C. Heinrich, Brian P. Rubin, B.Jack Longley, Jonathan A. Fletcher, Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations Human Pathology. ,vol. 33, pp. 484- 495 ,(2002) , 10.1053/HUPA.2002.124124
Christopher D.M. Fletcher, Jules J. Berman, Christopher Corless, Fred Gorstein, Jerzy Lasota, B.Jack Longley, Markku Miettinen, Timothy J. O'Leary, Helen Remotti, Brian P. Rubin, Barry Shmookler, Leslie H. Sobin, Sharon W. Weiss, Diagnosis of gastrointestinal stromal tumors: A consensus approach Human Pathology. ,vol. 33, pp. 459- 465 ,(2002) , 10.1053/HUPA.2002.123545
Christopher D.M. Fletcher, Heikki Joensuu, George D. Demetri, Margaret von Mehren, Charles D. Blanke, Annick D. Van den Abbeele, Burton Eisenberg, Peter J. Roberts, Michael C. Heinrich, David A. Tuveson, Samuel Singer, Milos Janicek, Jonathan A. Fletcher, Stuart G. Silverman, Sandra L. Silberman, Renaud Capdeville, Beate Kiese, Bin Peng, Sasa Dimitrijevic, Brian J. Druker, Christopher Corless, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of Medicine. ,vol. 347, pp. 472- 480 ,(2002) , 10.1056/NEJMOA020461